GLP-1 Agonists, Insulin and SGLT-2 Inhibitors in the Changing Treatment Paradigm: What are the Benefits, Risks and Outcomes in Patients with Type 2 Diabetes?

New Horizons in the Treatment and Management of Type 2 Diabetes: Individualizing Therapy with Novel Options for Improved Patient Outcomes is a 4-part series that will provide attendees with the latest information in Type 2 Diabetes Management

This is Part III of the series focusing on GLP-1 Agonists, Insulin and SGLT-2 Inhibitors in the Changing Treatment Paradigm: What are the Benefits, Risks and Outcomes in Patients with Type 2 Diabetes?

This activity is an archive from the webinar held on March 15, 2017

This activity is valid from valid for two years, from March 15, 2017 to March 30, 2019
 

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Lilly, USA LLC

Description:
The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.

Upon Completion of this activity, participants will be able to:

  • Review the latest clinical data on GLP-1 agonists, insulins and SGLT2 inhibitors

  • Recognize the most effective place in the T2DM treatment continuum for GLP-1 agonists, newer insulins and SGLT-2 inhibitors

  • Identify patients that would best be suited for a GLP-1 agonist therapy

  • Analyze the current role of insulins in the battle against type 2 diabetes in a changing treatment paradigm

  • Examine efficacy and safety results of the EMPA-REG Outcome trial and the potential benefits and risks of SGLT-2 inhibitors in people with T2DM, with or without cardiovascular disease

  • Review barriers to treatment of newer therapies in T2DM and strategies to overcome those barriers
     

Faculty: Tom Elasy, MD, MPH
Vanderbilt Diabetes Center, School of Medicine
Medical Director, Associate Professor

Disclosure:

Dr. Elasy has nothing to disclose.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by an educational grant from
Lilly, USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue